As of June 30, 2025, MBX Biosciences (MBX) had cash, cash equivalents and marketable securities of $224.9 million. Based on its current operating plan, management expects the combined cash, cash equivalents and marketable securities balance to fund operations into mid-2027.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBX:
- Block downgraded, Wayfair upgraded: Wall Street’s top analyst calls
- MBX Biosciences initiated with an Outperform at Mizuho
- Arm, Palantir upgraded: Wall Street’s top analyst calls
- MBX Biosciences initiated with an Outperform at Oppenheimer
- MBX Biosciences appoints Andreas Moraitis as SVP, clinical development